APOC3 inhibition decreased the lung adenocarcinoma (LUAD) risk (OR 0.60, 95% CI 0.43–0.84, p = 0.039) but increased SCLC risk (OR 2.18, 95% CI 1.17–4.09, p = 0.029) via ApoB reduction by 1 SD. This evidence concerns the gene APOB and lung adenocarcinoma.